Basic Aripiprazole Information

• INN (International Nonproprietary Name): Aripiprazole.
• Brand Names Available In Canada (English): not specified.
• ATC Code: N05AX12.
• Forms & Dosages: Tablets 2, 5, 10, 15, 20, 30 mg; Oral solution 1 mg/mL (not in all countries); Orally disintegrating tablets 10, 15 mg (selected brands); Long-acting depot injection 300 mg and 400 mg ("Abilify Maintena").
• Manufacturers In Canada (English): not specified.
• Registration Status In Canada (English): not specified.
• OTC / Rx Classification: Prescription-only (Rx).

Latest Research Highlights

What does the evidence since 2022 tell Canadians about aripiprazole?

Recent international systematic reviews and randomized controlled trials from 2022–2025 continue to support aripiprazole’s efficacy across schizophrenia and bipolar mania, and as adjunctive therapy in major depressive disorder.

Canadian investigator-initiated work during this period has emphasised real-world effectiveness and tolerability, especially adherence with long-acting injections and metabolic outcomes.

International pooled analyses reported relapse reduction with monthly long-acting injection formulations, a generally lower average weight and metabolic risk compared with olanzapine, and akathisia as a commonly reported tolerability concern.

Rare events documented in global safety data include neuroleptic malignant syndrome and cardiorespiratory complications in overdose scenarios.

Important evidence gaps remain, notably long-term comparative effectiveness in older adults and in Indigenous populations where trial representation is limited.

Data Highlights:

• Monthly LAI (Abilify Maintena) reported to reduce relapse compared with some comparators in pooled analyses, but specific relapse rates are not specified in the provided data.
• Akathisia remains a leading tolerability concern across trials and real-world studies, though incidence figures are not specified here.

Clinical Effectiveness In Canada

Is aripiprazole covered and commonly used in Canadian practice?

Health Canada has authorised aripiprazole for multiple psychiatric indications and the product is listed in public drug product resources with assigned DINs; exact DIN numbers were not specified here.

Provincial formularies commonly include aripiprazole in outpatient and mental-health formularies, though listing criteria and prior-authority rules vary by indication and by formulation (oral versus long-acting injection).

Clinicians often favour aripiprazole for schizophrenia maintenance and as adjunctive therapy in major depressive disorder because it typically has a more favourable metabolic and prolactin profile compared with some alternatives such as olanzapine.

• Ontario: coverage often requires prior-authority for long-acting injectables and documentation for maintenance use.
• British Columbia: PharmaCare listings frequently cover generics for outpatient oral therapy; LAI coverage may need special authorization.
• Quebec: RAMQ has specific listing and reimbursement rules and expects bilingual documentation for claims.
• Other provinces and territories: coverage and criteria vary; some require specialist recommendation for LAI funding.

Indications And Expanded Uses

What is aripiprazole approved for in routine practice, and when is it used off‑label?

Approved indications include schizophrenia (adult and adolescent dosing), bipolar I mania, adjunctive treatment of major depressive disorder at low adjunctive doses, irritability associated with autism spectrum disorder in paediatric ranges, and monthly intramuscular injection (Abilify Maintena) for schizophrenia maintenance.

Off‑label uses observed in Canadian clinical practice include augmentation for treatment‑resistant anxiety-spectrum conditions, behavioural control in selected neurocognitive disorders with caution due to dementia risk, and short‑term management of severe agitation.

Approved (Health Canada)

Schizophrenia, bipolar I mania, adjunctive major depressive disorder, irritability in autism, monthly IM injection for schizophrenia maintenance (Abilify Maintena).

Off‑Label (Clinical Practice)

Augmentation in anxiety-spectrum treatment resistance, short-term behavioural control in neurocognitive disorders with caution, and acute agitation management.

Composition And Brand Landscape

What is in the pill and which brands and generics are available?

The active ingredient is aripiprazole (International Nonproprietary Name), ATC code N05AX12.

Branded examples include Abilify and the long‑acting formulation Abilify Maintena.

Generics are widely available internationally from suppliers such as Teva and Mylan; several other manufacturers supply aripiprazole globally.

• Otsuka Pharmaceutical and Bristol‑Myers Squibb: original brand suppliers.
• Generics seen internationally: Teva, Mylan, Betapharm, Bexal, Cinfa, G.L. Pharma, Biosintética, Neuraxpharm, KRKA.

Note: DIN‑specific packaging and bilingual labelling are required in Canada, and the LAI product is often sourced and administered via specialised clinics rather than routine retail counters.

Contraindications And Special Precautions

Who should not take aripiprazole and what needs close attention?

An absolute contraindication is a known hypersensitivity to aripiprazole or to any excipient listed in the product monograph.

Health Canada and product monographs include a warning about increased mortality in elderly patients with dementia‑related psychosis, which is a class effect for antipsychotics.

Use caution in severe hepatic or renal impairment and in people with cardiovascular disease, seizure history, or diabetes and metabolic risk factors.

• Monitor weight and body mass index at baseline and periodically.
• Check fasting glucose and lipid profile at baseline and during follow-up.
• Assess for extrapyramidal symptoms, akathisia, and signs of neuroleptic malignant syndrome.
• Consider ECG monitoring when combining with other QT‑prolonging drugs or in patients with cardiac risk.

Data Highlight: There is a dementia‑related mortality warning for elderly patients that requires careful, documented risk/benefit discussion before initiation.

Dosage Guidelines

What doses are used in Canada and how should they be adjusted?

Standard adult dosing: schizophrenia typically 10–15 mg once daily (maximum 30 mg/day).

Bipolar I mania typical dose is 15 mg/day (maximum 30 mg/day).

Adjunctive use in major depressive disorder is usually low dose, 2–5 mg/day, with up‑titration up to 15 mg where indicated.

For irritability in autism, paediatric ranges from 2 mg starting dose up to 15 mg/day depending on response and tolerability.

Abilify Maintena LAI: common regimen is 400 mg IM once monthly with an oral aripiprazole overlap for 14 days at initiation; 300 mg is an alternative maintenance dose for selected patients.

Missed‑dose rules:

• Oral: take as soon as remembered unless it is near the time of the next dose; do not double the next dose.
• LAI: contact the prescriber or clinic urgently; gaps beyond recommended windows may require oral restart or alternative scheduling and specialist advice.

Interactions Overview

Which medicines and lifestyle factors can affect aripiprazole?

Aripiprazole is metabolised primarily by CYP2D6 and CYP3A4 enzymes.

Strong CYP3A4 inhibitors or CYP2D6 inhibitors such as some azole antifungals and selective serotonin reuptake inhibitors (for example, fluoxetine and paroxetine) can raise aripiprazole plasma concentrations.

CYP3A4 inducers like carbamazepine can reduce aripiprazole exposure and potentially lower efficacy.

Pharmacodynamic interactions include additive CNS depression with alcohol, benzodiazepines and opioids.

• Major drug interactions: fluoxetine, paroxetine, ketoconazole (as strong inhibitors); carbamazepine (inducer).
• Watch for additive sedation with alcohol and cannabis; counsel patients about impaired driving and operating machinery.

CYP2D6

A liver enzyme affecting aripiprazole metabolism; inhibitors increase drug levels.

CYP3A4

A major metabolic pathway; inducers reduce, and inhibitors increase aripiprazole levels.

Data Highlight: Clinically significant inhibitors include fluoxetine and paroxetine; carbamazepine is a clinically significant inducer requiring dose or monitoring adjustments.

Cultural Perceptions And Patient Habits

What patients in Canada say about aripiprazole and how does access shape use?

Online Canadian patient forums report mixed experiences with aripiprazole: many value symptom control and relatively lower weight gain compared with some alternatives, and others report bothersome akathisia or daytime sedation.

Bilingual labelling and French‑language counselling are expected in Quebec and commonly available at large pharmacy chains.

Stigma around antipsychotics persists and can influence patient preference for lower doses or for long‑acting injections to avoid daily pill burden.

Rural communities often have limited access to psychiatrists and LAI clinics, making community pharmacists key contact points for counselling and follow-up.

For Indigenous patients, culturally safe care and co‑designed monitoring plans are important to address historical mistrust and higher chronic disease prevalence.

• Common patient concerns: weight changes, akathisia, sexual side effects, daily pill burden, and injection logistics.
• Urban vs Rural: urban centres generally have faster specialist access; rural settings may need telepsychiatry or public health nurse support for LAI administration.

Availability And Pricing Patterns

Where can Canadians get aripiprazole and what affects cost?

Aripiprazole is prescription‑only in Canada, with retail chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs stocking brand and generic oral forms.

Long‑acting injectables, including Abilify Maintena, are frequently dispensed through hospital clinics or specialty pharmacies rather than standard retail counters.

Coverage varies by province, with oral generics generally easier to list and LAI coverage usually requiring specialty authorisation.

Online Canadian pharmacies may supply generics with a valid prescription, while cross‑border importation from the United States is legally restricted and poses regulatory and quality differences.

• Coverage steps: confirm prescriber documentation, submit prior‑authorization where required (Ontario Drug Benefit, BC PharmaCare, RAMQ), and coordinate with a specialty pharmacy for LAI funding.
• In our online pharmacy, aripiprazole is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Comparable Medicines And Preferences

What are common alternatives and how do they compare?

Alternative antipsychotics available in Canada include risperidone, olanzapine, quetiapine, paliperidone, lurasidone and ziprasidone.

Pros and cons checklist:

• Risperidone: effective for psychosis but associated with higher prolactin elevations.
• Olanzapine: potent antipsychotic efficacy but higher risk of weight gain and metabolic complications.
• Quetiapine: sedating, useful when insomnia is comorbid, but may cause metabolic changes.
• Paliperidone: available as LAI options; metabolic and extrapyramidal tradeoffs need consideration.
• Lurasidone: favourable metabolic profile but limited LAI availability.

Frequently Asked Questions

Will aripiprazole make me gain weight?

Many patients experience less weight gain with aripiprazole compared with olanzapine, but weight and metabolic changes can still occur.

Baseline and periodic monitoring of BMI, fasting glucose and lipids is recommended.

Can I drink alcohol while taking aripiprazole?

Alcohol can increase sedation and impair judgment when combined with aripiprazole.

Avoid excessive alcohol and discuss any regular alcohol use with the prescriber.

What if I miss a dose or an injection?

For oral doses, take as soon as remembered unless it is close to the next scheduled dose; do not double doses.

For long‑acting injections, contact the clinic urgently because long gaps may require oral overlap or dose adjustments per product guidance.

Are there special considerations for seniors?

Yes — start at lower doses, monitor for orthostatic hypotension, somnolence and metabolic changes, and discuss dementia‑related risks carefully before use.

Data Highlight: If an LAI dose is missed beyond the recommended window, clinics typically follow product monograph guidance which may include oral restarting and specialist review.

Guidelines For Proper Use

How should pharmacists and prescribers manage aripiprazole safely in Canada?

Pharmacist counselling checklist:

• Confirm the indication and whether prior authorisation is required for the patient’s provincial plan.
• Review concomitant medications for CYP2D6 and CYP3A4 interactions and pharmacodynamic risks.
• Counsel patients on signs of akathisia, EPS and neuroleptic malignant syndrome and advise when to seek urgent care.
• Advise on storage: tablets at 15–30°C in original packaging; injectable per product label and avoid freezing.
• Provide bilingual written materials where required, especially for patients in Quebec.

Monitoring Schedule

Baseline: weight/BMI, fasting glucose, lipids, blood pressure, and relevant ECG if cardiac risk present.

1 Month: assess side effects and adherence; weight check.

3 Months: repeat fasting glucose and lipids, reassess metabolic risk.

Ongoing: periodic metabolic monitoring every 6–12 months or sooner if abnormalities arise.

Delivery Across Canada (English)